Cerity Partners
RXRX icon

Cerity Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Cerity Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$292K Buy
79,694
+15,775
+25% +$52.5K ﹤0.01% 2817
2026
Q1 		$196K Sell
63,919
-6,362
-9% -$24.6K ﹤0.01% 2888
2025
Q4 		$287K Buy
70,281
+8,732
+14% +$43.3K ﹤0.01% 2435
2025
Q3 		$300K Buy
61,549
+795
+1% +$4.17K ﹤0.01% 2282
2025
Q2 		$307K Sell
60,754
-1,937
-3% -$9.52K ﹤0.01% 2145
2025
Q1 		$332K Buy
+62,691
New +$457K ﹤0.01% 1972

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cerity Partners's RXRX Position: Q2 2026 in Review

Cerity Partners increased its Recursion Pharmaceuticals (RXRX) stake by 25% in Q2 2026, buying an estimated $52.5K and bringing the position to 79,694 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

Cerity Partners first reported a position in RXRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $332K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Cerity Partners held 79,694 shares of Recursion Pharmaceuticals worth $292K as of Q2 2026.
  • Cerity Partners bought 15,775 Recursion Pharmaceuticals shares in Q2 2026, an estimated $52.5K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2817 holding.
  • Cerity Partners first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Cerity Partners's Recursion Pharmaceuticals position peaked at $332K in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.